Description
RJ-34, an aristolactam analogue, exhibits potent antitumor activities against a broad array of cancer cell lines with GI50 values in the subnanomolar range (GI50 <0.1 nM for A431, MES-SA, MES-SA/DX5, HCT-15, and HCT-15/CLO2 cells).
Product information
CAS Number: 1170694-29-7
Molecular Weight: 394.42
Formula: C22H22N2O5
Smiles: CN(C)CCN1C(=O)C2=CC(OC)=C(OC)C3=C2C1=CC1=C2OCOC2=CC=C13
InChiKey: XEOKAJIDDOWYMB-UHFFFAOYSA-N
InChi: InChI=1S/C22H22N2O5/c1-23(2)7-8-24-15-9-13-12(5-6-16-20(13)29-11-28-16)19-18(15)14(22(24)25)10-17(26-3)21(19)27-4/h5-6,9-10H,7-8,11H2,1-4H3
Technical Data
Appearance: Solid Power
Purity: ≥98% (or refer to the Certificate of Analysis)
Solubility: To be determined
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥12 months if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined
HS Tariff Code: 382200
References:
- Nafie MS, et al. Exploration of novel VEGFR2 tyrosine kinase inhibitors via design and synthesis of new alkylated indolyl-triazole Schiff bases for targeting breast cancer. Bioorg Chem. 2022;122:105708.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.